阿斯利康表示，将开始直接在美国销售一款中国生产的抗癌药，此前因该公司将该疗法引入美国患者的速度过慢而受到批评。
AstraZeneca said it will begin selling a China-made cancer drug directly in the United States after criticism that it was too slow to bring the treatment to American patients.
此前一些美国患者曾前往上海获取该药物，而美国监管机构早已批准了该药。
Some US patients had previously traveled to Shanghai to obtain the medicine, which American regulators had already approved.
此举凸显了全球两大制药市场在定价和供应方面差距日益引发的不满。
The move highlights growing frustration over pricing and availability gaps between the world's two largest pharmaceutical markets.